Cargando…

Advances in the Preoperative Identification of Uterine Sarcoma

SIMPLE SUMMARY: As a lethal malignant tumor, uterine sarcomas lack specific diagnostic criteria due to their similar presentation with uterine fibroids, clinicians are prone to make the wrong diagnosis or adopt incorrect treatment methods, which leads to rapid tumor progression and increased metasta...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Junxiu, Wang, Zijie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318633/
https://www.ncbi.nlm.nih.gov/pubmed/35884577
http://dx.doi.org/10.3390/cancers14143517
_version_ 1784755341384220672
author Liu, Junxiu
Wang, Zijie
author_facet Liu, Junxiu
Wang, Zijie
author_sort Liu, Junxiu
collection PubMed
description SIMPLE SUMMARY: As a lethal malignant tumor, uterine sarcomas lack specific diagnostic criteria due to their similar presentation with uterine fibroids, clinicians are prone to make the wrong diagnosis or adopt incorrect treatment methods, which leads to rapid tumor progression and increased metastatic propensity. In recent years, with the improvement of medical level and awareness of uterine sarcoma, more and more studies have proposed new methods for preoperative differentiation of uterine sarcoma and uterine fibroids. This review outlines the up-to-date knowledge about preoperative differentiation of uterine sarcoma and uterine fibroids, including laboratory tests, imaging examinations, radiomics and machine learning-related methods, preoperative biopsy, integrated model and other relevant emerging technologies, and provides recommendations for future research. ABSTRACT: Uterine sarcomas are rare malignant tumors of the uterus with a high degree of malignancy. Their clinical manifestations, imaging examination findings, and laboratory test results overlap with those of uterine fibroids. No reliable diagnostic criteria can distinguish uterine sarcomas from other uterine tumors, and the final diagnosis is usually only made after surgery based on histopathological evaluation. Conservative or minimally invasive treatment of patients with uterine sarcomas misdiagnosed preoperatively as uterine fibroids will shorten patient survival. Herein, we will summarize recent advances in the preoperative diagnosis of uterine sarcomas, including epidemiology and clinical manifestations, laboratory tests, imaging examinations, radiomics and machine learning-related methods, preoperative biopsy, integrated model and other relevant emerging technologies.
format Online
Article
Text
id pubmed-9318633
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93186332022-07-27 Advances in the Preoperative Identification of Uterine Sarcoma Liu, Junxiu Wang, Zijie Cancers (Basel) Review SIMPLE SUMMARY: As a lethal malignant tumor, uterine sarcomas lack specific diagnostic criteria due to their similar presentation with uterine fibroids, clinicians are prone to make the wrong diagnosis or adopt incorrect treatment methods, which leads to rapid tumor progression and increased metastatic propensity. In recent years, with the improvement of medical level and awareness of uterine sarcoma, more and more studies have proposed new methods for preoperative differentiation of uterine sarcoma and uterine fibroids. This review outlines the up-to-date knowledge about preoperative differentiation of uterine sarcoma and uterine fibroids, including laboratory tests, imaging examinations, radiomics and machine learning-related methods, preoperative biopsy, integrated model and other relevant emerging technologies, and provides recommendations for future research. ABSTRACT: Uterine sarcomas are rare malignant tumors of the uterus with a high degree of malignancy. Their clinical manifestations, imaging examination findings, and laboratory test results overlap with those of uterine fibroids. No reliable diagnostic criteria can distinguish uterine sarcomas from other uterine tumors, and the final diagnosis is usually only made after surgery based on histopathological evaluation. Conservative or minimally invasive treatment of patients with uterine sarcomas misdiagnosed preoperatively as uterine fibroids will shorten patient survival. Herein, we will summarize recent advances in the preoperative diagnosis of uterine sarcomas, including epidemiology and clinical manifestations, laboratory tests, imaging examinations, radiomics and machine learning-related methods, preoperative biopsy, integrated model and other relevant emerging technologies. MDPI 2022-07-20 /pmc/articles/PMC9318633/ /pubmed/35884577 http://dx.doi.org/10.3390/cancers14143517 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Liu, Junxiu
Wang, Zijie
Advances in the Preoperative Identification of Uterine Sarcoma
title Advances in the Preoperative Identification of Uterine Sarcoma
title_full Advances in the Preoperative Identification of Uterine Sarcoma
title_fullStr Advances in the Preoperative Identification of Uterine Sarcoma
title_full_unstemmed Advances in the Preoperative Identification of Uterine Sarcoma
title_short Advances in the Preoperative Identification of Uterine Sarcoma
title_sort advances in the preoperative identification of uterine sarcoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318633/
https://www.ncbi.nlm.nih.gov/pubmed/35884577
http://dx.doi.org/10.3390/cancers14143517
work_keys_str_mv AT liujunxiu advancesinthepreoperativeidentificationofuterinesarcoma
AT wangzijie advancesinthepreoperativeidentificationofuterinesarcoma